Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for life-threatening diseases, primarily HIV, Hepatitis B, and fungal infections. Key products include Truvada, Atripla, Viread, Emtriva, Hepsera, and AmBisome. The company also earns significant royalties from Tamiflu (marketed by Roche) and Macugen (marketed by OSI Pharmaceuticals).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenues | $1,058,803 | $3,135,322 |
| Net Income | $398,319 | $1,213,656 |
| Diluted EPS | $0.42 | $1.26 |
| Operating Cash Flow (9mo) | $1,253,412 | |
| Cash & Marketable Securities | $2,218,051 (as of Sep 30, 2007) | |
| Working Capital | $1,853,604 (as of Sep 30, 2007) | |
| Convertible Senior Notes | $1,300,000 (Long-term liability) | |
| Product Gross Margin | 79% | 80% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 41% year-over-year for the quarter ($1.06B vs. $749M) and 47% for the nine-month period ($3.14B vs. $2.13B). This was driven primarily by a 45% increase in HIV product sales.
- Profitability: Net income turned from a loss of $52.2M in Q3 2006 to a profit of $398.3M in Q3 2007. The prior year loss was significantly impacted by a $355.6M non-deductible charge for purchased in-process research and development (IPR&D) related to the Corus acquisition.
- Product Mix: Atripla sales surged 253% in Q3 2007 compared to Q3 2006, while Viread and Emtriva sales declined due to cannibalization by the combination product Atripla.
- Acquisitions: Completed the acquisition of Nycomed Limited in September 2007 for $47.5 million to expand manufacturing capabilities in Ireland. Updated the purchase price allocation for the Myogen acquisition, increasing net deferred tax assets.
- Stock Repurchases: Repurchased $454.9 million of common stock in May and June 2007. In October 2007, the Board authorized a new $3.0 billion repurchase program.
Guidance, Outlook, and Risks
- Product Launches & Approvals: Letairis (ambrisentan) was launched in the U.S. in June 2007. Atripla received approval in Canada in October 2007, and a positive opinion was issued by the European Medicines Agency (EMEA) for Atripla, with a decision expected in Q4 2007.
- Pipeline Updates:
- HIV: Anticipates dosing first patients in a Phase 3 study for elvitegravir (GS 9137) in H1 2008.
- Hepatitis B: Filed a supplemental NDA for Viread for chronic hepatitis B in October 2007.
- Respiratory: Plans to submit an NDA for aztreonam lysine for inhalation (cystic fibrosis) in Q4 2007.
- Financial Outlook: Management expects full-year 2007 product gross margins to be lower than 2006 due to the higher mix of Atripla sales (which includes a zero-margin component for the Sustiva ingredient). R&D and SG&A expenses are expected to be higher than 2006 levels due to new product launches and acquisitions.
- Risks & Contingencies:
- Tamiflu Dependency: Royalty revenue from Tamiflu is volatile and dependent on Roche's sales and global pandemic planning. A decrease in Tamiflu sales would disproportionately affect pre-tax income.
- Regulatory & Safety: Risks regarding the approval of pipeline products (e.g., darusentan, aztreonam lysine) and potential safety issues with marketed products (e.g., Letairis liver injury risks).
- Patent Challenges: The Public Patent Foundation requested reexamination of four patents related to tenofovir disoproxil fumarate (active ingredient in Truvada, Atripla, Viread).
- Accounting Changes: Potential impact of proposed FASB guidance on convertible debt (Instrument C), which could increase reported interest expense by approximately $38 million for the nine months ended Sep 30, 2007.
Investor Verification Checklist
- Atripla Margin Impact: Verify the long-term sustainability of gross margins given the zero-margin Sustiva component within Atripla sales.
- Tamiflu Royalty Volatility: Assess the risk of fluctuating pre-tax income due to the unpredictable nature of Tamiflu sales driven by pandemic planning.
- Pipeline Execution: Monitor the timeline and success of the aztreonam lysine NDA submission (Q4 2007) and the elvitegravir Phase 3 trial initiation (H1 2008).
- Patent Litigation: Track the outcome of the PTO reexamination requests regarding tenofovir disoproxil fumarate patents.
- Accounting Standards: Confirm the final impact of the proposed FASB Staff Position on convertible debt accounting on future interest expense and net income.